A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects

International Journal of Cancer

Volumn 131, Issue 3, 2012, Pages

  Abbas, Richat ^a   Hug, Bruce A ^a   Leister, Cathie ^a   Sonnichsen, Daryl ^a  

^a PFIZER INC   (United States)

Author keywords

bosutinib; cardiac repolarization; pharmacokinetics; QT interval; SKI 606

Indexed keywords

BOSUTINIB; KETOCONAZOLE; MOXIFLOXACIN; PLACEBO;

ABDOMINAL PAIN; ADULT; APPLICATION SITE DERMATITIS; AREA UNDER THE CURVE; ARTICLE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUTROPHIL COUNT; NORMAL HUMAN; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SYNCOPE; TIME TO MAXIMUM PLASMA CONCENTRATION; TORSADE DES POINTES; VOMITING;

EID: 84861570294     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27348     Document Type: Article

References (24)

1. ICH E14 Guidance: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-arrhythmic drugs. Federal Register 2005; 70: 61134-5.
2. Morganroth J,. Cardiac repolarization and the safety of new drugs defined by electrocardiography. Clin Pharmacol Ther 2007; 81: 108-13.
3. Glassman AH, Bigger JT,. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158: 1174-82.
4. Shah RR,. The significance of QT interval in drug development. Br J Clin Pharmacol 2002; 54: 188-202.
5. Curigliano G, Spitaleri G, Fingert HJ, de Braud F, Sessa C, Loh E, Cipolla C, De Pas T, Goldhirsch A, Shah R,. Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development. Eur J Cancer 2008; 44: 494-500.
6. Munster PN, Rubin EH, Van Belle S, Friedman E, Patterson JK, Van Dyck K, Li X, Comisar W, Chodakewitz JA, Wagner JA, Iwamoto M,. A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. Clin Cancer Res 2009; 15: 7077-84.
7. Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, Ahmed S, Redaelli S, Piazza R, Magistroni V, Andreoni F, Scapozza L, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 2006; 66: 11314-22.
8. Boschelli DH, Wang YD, Johnson S, Wu B, Ye F, Barrios Sosa AC, Golas JM, Boschelli F,. 7-Alkoxy-4-phenylamino-3-quinolinecar-bonitriles as dual inhibitors of Src and Abl kinases. J Med Chem 2004; 47: 1599-601.
9. Thomas SM, Brugge JS,. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Bio 1997; 13: 513-609.
10. Windham TC, Parikh NU, Siwak DR, Summy JM, McConkey DJ, Kraker AJ, Gallick GE,. Src activation regulates anoikis in human colon tumor cell lines. Oncogene 2002; 21: 7797-807.
11. Fizazi K,. The roles of Src in prostate cancer. Ann Oncol 2007; 18: 1765-73.
12. Campone M, Bondarenko I, Brincat S, et al. Preliminary results of a phase 2 study of bosutinib (SKI-606), a dual Src/Abl kinase inhibitor, in patients with advanced breast cancer. Breast Cancer Res Treat 2007; 106: S268. Abstract 6062.
13. Cortes J, Kantarjian H, Brümmendorf T, Khoury HJ, Kim D, Turkina A, Volkert A, Wang J, Arkin S, Gambacorti-Passerini C,. Safety and efficacy of bosutinib (SKI-606) in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib (IM). J Clin Oncol 2010; 28 (suppl 15). Abstract 6502.
14. Gambacorti-Passerini C, Pogliani EM, Baccarani M, Martinelli G, Kantarjian HM, Chandy M, Khoury HJ, Kim D-W, Brummendorf TH, Arkin S, Cortes J,. Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated in patients with AP and BP CML and Ph+ ALL. Blood 2008; 112. Abstract 1101.
15. Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D,. Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects. J Clin Pharmacol, in press.
16. Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D,. Ascending single-dose study of safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy subjects. Mol Cancer Ther 2009; 8 (suppl 1). Abstract B215.
17. Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D,. Assessment of the effect of a high-fat meal on the relative bioavailability and pharmacokinetics of bosutinib (SKI-606), a dual inhibitor of Src and Abl tyrosine kinases, in healthy subjects. Clin Pharm Ther 2010; 87 (suppl 1). Abstract PIII-61.
18. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 2003; 43: 443-69.
19. Hug B, Abbas R, Leister C, Burns J, Sonnichsen D,. A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects. Clin Cancer Res 2010; 16: 4016-23.
20. Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, 3rd ed. Vancouver: Lippincott Williams & Wilkins, 1992.
21. Gambacorti-Passerini C, Brümmendorf TH, Kantarjian H, Martinelli G, Liu D, Fisher T, Hewes B, Volkert A, Abbas R, Cortes J,. Bosutinib exhibits clinical activity in patients with Philadelphia chromosome positive CML or ALL patients who failed imatinib. J Clin Oncol (ASCO Annual Meeting Abstracts) 2007; 25 (Suppl 18S). Abstract 7006.
22. Stass H, Dalhoff A, Kubitza D, Schuhly U,. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 1998; 42: 2060-5.
23. Viskin S,. Long QT syndromes and torsade de pointes. Lancet 1999; 354: 1625-33.
24. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, et al., eds. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute. Available at:. Accessed November 22, 2011.